Use of 3,4-Dideoxykanamycin B (DKB) in Various Infections

  • Sutemi Oka
Part of the Chemotherapy book series (CT, volume 2)


A new antibiotic, 3′,4′-dideoxykanamycin B, discovered by Prof. Umezawa, and abbreviated as DKB, was synthetized on the theory that its mechanism was not apt to succumb to inactivation by bacilli resistant to kanamycin B. Clinical use of DKB, with its commercial preparation named ‘Panimycin’, was started in January of this year following the acceptance by the Ministry of Welfare of the findings on the animal toxicity, teratogenicity, and human pharmacology of the drug and on double blind clinical trials.


Pseudomonas Aeruginosa Klebsiella Pneumoniae Pulmonary Tuberculosis Double Blind Clinical Trial Complicated Urinary Tract Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1).
    Umezawa, H., Umezawa, S., Tsuchiya, T. and Okazaki, Y. (1971), J. Antibiotics, 24, 485.CrossRefGoogle Scholar
  2. 2).
    Symposium on New Antibiotics, DKB (3’,4’-dideoxykanamycin B) (1973), Chemotherapy, 21, 597 (in Japanese).Google Scholar

Copyright information

© Springer Science+Business Media New York 1976

Authors and Affiliations

  • Sutemi Oka
    • 1
  1. 1.Institute of Microbial ChemistryShinagawa-ku, TokyoJapan

Personalised recommendations